The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome–positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study
Open accessAbstract
The combination of imatinib with chemotherapy has been recently reported as very promising in patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). During 2004 and 2005, 45 patients with newly diagnosed Ph+ ALL were treated in the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAAPH) 2003 study, in which imatinib was started with HAM (mitoxantrone with intermediate-dose cytarabine) consolidation in good early responders (corticosensitive and chemosensitive ALL) or earlier during the induction course in combination with dexamethasone and vincristine in poor early responders (corticoresistant and/or chemoresistant ALL). Imatinib was then continuously administered until stem cell transplantation (SCT). Overall, complete remission (CR) and BCR-ABL real-time quantitative polymerase chain reaction (RQ-PCR) negativity rates were 96% and 29%, respectively. All of the 22 CR patients (100%) with a donor actually received allogeneic SCT in first CR. At 18 months, the estimated cumulative incidence of relapse, disease-free survival, and overall survival were 30%, 51%, and 65%, respectively. These 3 end points compared very favorably with results obtained in the pre-imatinib LALA-94 trial. This study confirms the value of the combined approach and encourages prospective trials to define the optimal chemotherapy that has to be combined with imatinib and to carefully reevaluate the place of allogeneic SCT in this new context.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gabert, J., Beillard, E., van der Velden, V. H. J., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J. M., Cavé, H., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403135 · Cited by 1,284
Self-citationResults of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
Kantarjian, H. M., O’Brien, S., Smith, T. L., Cortes, J., Giles, F. J., Beran, M., Pierce, S., Huh, Y., Andreeff, M., Koller, C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.547 · Cited by 796
Ottmann, O. G. (2002) · Blood · doi:10.1182/blood-2001-12-0181 · Cited by 555
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
Thomas, X., Boiron, J.-M., Huguet, F., Dombret, H., Bradstock, K., Vey, N., Kovacsovics, T., Delannoy, A., Fegueux, N., Fenaux, P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.050 · Cited by 550
Self-citationYanada, M., Takeuchi, J., Sugiura, I., Akiyama, H., Usui, N., Yagasaki, F., Kobayashi, T., Ueda, Y., Takeuchi, M., Miyawaki, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2177 · Cited by 454
Dombret, H. (2002) · Blood · doi:10.1182/blood-2002-03-0704 · Cited by 378
Self-citationRéa, D., Legros, L., Raffoux, E., Thomas, X., Turlure, P., Maury, S., Dupriez, B., Pigneux, A., Choufi, B., Reman, O., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404115 · Cited by 76
Self-citation
Cited by
Pui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Malard, F., & Mohty, M. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33018-1 · Cited by 773
Huguet, F., Leguay, T., Raffoux, E., Thomas, X., Beldjord, K., Delabesse, E., Chevallier, P., Buzyn, A., Delannoy, A., Chalandon, Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6916 · Cited by 567
Self-citationDasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
Foà, R., Bassan, R., Vitale, A., Elia, L., Piciocchi, A., Puzzolo, M.-C., Canichella, M., Viero, P., Ferrara, F., Lunghi, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2016272 · Cited by 522
Modern Therapy of Acute Lymphoblastic Leukemia
Bassan, R., & Hoelzer, D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1382 · Cited by 485
Metadata
- Authors
- de Labarthe, A., Rousselot, P., Huguet-Rigal, F., Delabesse, E., Witz, F., Maury, S., Réa, D., Cayuela, J.-M., Vekemans, M.-C., Reman, O., Buzyn, A., Pigneux, A., Escoffre, M., Chalandon, Y., MacIntyre, E., Lhéritier, V., Vernant, J.-P., Thomas, X., Ifrah, N., Dombret, H., & for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2006-10-24
- Volume
- 109
- Issue
- 4
- Pages
- 1408-1413
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2000116184
- Cited by
- 344
- References
- 9
- FWCI
- 26.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome–positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. https://app.cochat.ai/papers/10.1182/blood-2006-03-011908
- The paper
- de Labarthe, A., Rousselot, P., Huguet-Rigal, F., Delabesse, E., Witz, F., Maury, S., Réa, D., Cayuela, J.-M., Vekemans, M.-C., Reman, O., Buzyn, A., Pigneux, A., Escoffre, M., Chalandon, Y., MacIntyre, E., Lhéritier, V., Vernant, J.-P., Thomas, X., Ifrah, N., . . . for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). (2007). Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome–positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. https://doi.org/10.1182/blood-2006-03-011908
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.